Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Collegium Pharmaceutical (COLL)

Collegium Pharmaceutical shareholders approve 2025 Equity Incentive Plan and all eight directors

Neutral Impact 3 of 5 shareholder Written later

At its May 15, 2025 annual meeting, Collegium Pharmaceutical shareholders elected all eight director nominees and approved the 2025 Equity Incentive Plan, which allows stock-based awards to officers, directors and employees. Shareholders also approved executive pay on an advisory basis and chose annual advisory votes on pay, and ratified Deloitte & Touche LLP as auditor for 2025.

Key points

  • Plan approval: 20,255,783 for, 7,143,482 against, 245,956 abstentions, 1,449,301 broker non-votes
  • Eight directors elected to serve until the 2026 Annual Meeting; Nancy Lurker received 25,089,514 for votes
  • Shareholders preferred an advisory pay vote every one year (26,389,740 votes)
  • 29,094,522 of 32,131,798 eligible shares were present in person or by proxy

The filing

CompanyCollegium Pharmaceutical (COLL)
Form8-K, current report
Filed with the SECMay 19, 2025, 4:05 PM ET
Accession number0001104659-25-050435

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 19, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.